Personalized gene therapy aims to heal unhealable wounds
NCT ID NCT06892639
Summary
This study is testing a personalized cell therapy called D-Fi to see if it helps heal stubborn wounds in people with dystrophic epidermolysis bullosa (DEB), a painful genetic condition that causes fragile, blistering skin. In the trial, each participant's own skin cells are genetically modified and injected into one of their wounds, while another similar wound is left untreated for comparison. The goal is to see if this new treatment, given alongside standard care, leads to better and faster wound closure than standard care alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Mission Dermatology
Santa Margarita, California, 92688, United States
-
Stanford University School of Medicine, Dermatology
Redwood City, California, 94063, United States
-
University of Massachusetts
Worcester, Massachusetts, 01655, United States
Conditions
Explore the condition pages connected to this study.